Preventing deaths due to the hypertensive disorders of pregnancy

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 36, Issue , 2016, Pages 83-102

  von Dadelszen, Peter ^a,b   Magee, Laura A ^a,b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

maternal mortality; medical interventions; pregnancy hypertension; societal interventions

Indexed keywords

ANTITHROMBOCYTIC AGENT; CORTICOSTEROID; PROTEIN; ACETYLSALICYLIC ACID; CALCIUM;

BLOOD PRESSURE MEASUREMENT; CLINICAL EFFECTIVENESS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DISEASE SURVEILLANCE; FETUS RISK; FOOD SECURITY; HEALTH INSURANCE; HUMAN; MALNUTRITION; MARRIAGE; MATERNAL HYPERTENSION; MATERNAL MORBIDITY; MATERNAL MORTALITY; MOBILIZATION; NEUROPROTECTION; NEWBORN MORBIDITY; NEWBORN MORTALITY; NON COMMUNICABLE DISEASE; PREECLAMPSIA; PREGNANCY; PREGNANT WOMAN; PRENATAL CARE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEIZURE; STILLBIRTH; SURVIVAL RATE; SUSTAINABLE DEVELOPMENT; VITAMIN SUPPLEMENTATION; CARDIOTOCOGRAPHY; CATERING SERVICE; COMPLICATION; DIETARY SUPPLEMENT; ECLAMPSIA; ETIOLOGY; FAMILY PLANNING; FEMALE; HEALTH CARE FACILITY; HYPERTENSION; HYPERTENSION, PREGNANCY-INDUCED; MASS SCREENING; MATERNAL DEATH; NEWBORN; OBESITY; PATIENT PARTICIPATION; PERINATAL DEATH; PRE-ECLAMPSIA; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREPREGNANCY CARE; PREVENTION AND CONTROL; PROTEINURIA; REPRODUCTIVE BEHAVIOR;

ASPIRIN; BIRTH INTERVALS; CALCIUM; CARDIOTOCOGRAPHY; DIETARY SUPPLEMENTS; ECLAMPSIA; FEMALE; FOOD SUPPLY; HEALTH FACILITIES; HUMANS; HYPERTENSION; HYPERTENSION, PREGNANCY-INDUCED; INFANT, NEWBORN; MASS SCREENING; MATERNAL DEATH; OBESITY; PATIENT PARTICIPATION; PERINATAL DEATH; PLATELET AGGREGATION INHIBITORS; PRE-ECLAMPSIA; PRECONCEPTION CARE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PRENATAL CARE; PROTEINURIA; REPRODUCTIVE BEHAVIOR; STILLBIRTH;

EID: 84994537738     PISSN: 15216934     EISSN: 15321932     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2016.05.005     Document Type: Review

References (102)

1. [1] Mol, B.W., Roberts, C.T., Thangaratinam, S., et al. Pre-eclampsia. Lancet, 2015 September 2.
2. [2] Steegers, E.A., von Dadelszen, P., Duvekot, J.J., et al. Pre-eclampsia. Lancet 376:9741 (2010 August 21), 631–644.
3. [3] Magee, L.A., Pels, A., Helewa, M., et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens 4:2 (2014 April), 105–145.
4. [4] Martin, J.N. Jr., Thigpen, B.D., Moore, R.C., et al. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 105:2 (2005 February), 246–254.
5. [5] Schutte, J.M., Schuitemaker, N.W., van Roosmalen, J., et al. Substandard care in maternal mortality due to hypertensive disease in pregnancy in the Netherlands. BJOG 115:6 (2008 May), 732–736.
6. [6] Lewis, G., Saving mothers' lives: reviewing maternal deaths to make motherhood safer. The 7th report of the Confidential Enquiries into Maternal Deaths in the United Kingdom., 2007, Confidential Enquiry into Maternal and Child Health, London.
7. [7] Cantwell, R., Clutton-Brock, T., Cooper, G., et al. Saving mothers' lives: reviewing maternal deaths to make motherhood safer: 2006-2008. The eighth report of the confidential enquiries into maternal deaths in the United Kingdom. BJOG 118:Suppl. 1 (2011 March), 1–203.
8. [8] Cote, A.M., Firoz, T., Mattman, A., et al. The 24-hour urine collection: gold standard or historical practice?. Am J Obstet Gynecol 199:6 (2008 December), 625–626.
9. [9] K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:2 Suppl. 1 (2002 February), S1–S266.
10. [10] Payne, B.A., Hutcheon, J.A., Ansermino, J.M., et al. A risk prediction model for the assessment and triage of women with hypertensive disorders of pregnancy in low-resourced settings: the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) multi-country prospective cohort study. PLoS Med, 11(1), 2014 January, e1001589.
11. [11] von Dadelszen, P., Payne, B., Li, J., et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet 377:9761 (2011 January 15), 219–227.
12. [12] Gruslin, A., Lemyre, B., Pre-eclampsia: fetal assessment and neonatal outcomes. Best Pract Res Clin Obstet Gynaecol 25:4 (2011 August), 491–507.
13. [13] Knight, M., Eclampsia in the United Kingdom 2005. BJOG 114:9 (2007 September), 1072–1078.
14. [14] Kassebaum, N.J., Bertozzi-Villa, A., Coggeshall, M.S., et al. Global, regional, and national levels and causes of maternal mortality during 1990-–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384:9947 (2014 September 13), 980–1004.
15. [15] Hutcheon, J.A., Lisonkova, S., Joseph, K.S., Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 25:4 (2011 August), 391–403.
16. [16] Thaddeus, S., Maine, D., Too far to walk: maternal mortality in context. Soc Sci Med 38:8 (1994 April), 1091–1110.
17. [17] Lotufo, F.A., Parpinelli, M.A., Haddad, S.M., et al. Applying the new concept of maternal near-miss in an intensive care unit. Clinics (Sao Paulo) 67:3 (2012), 225–230.
18. [18] Naderi, T., Foroodnia, S., Omidi, S., et al. Incidence and correlates of maternal near miss in Southeast Iran. Int J Reprod Med, 2015, 2015, 914713.
19. [19] Tuncalp, O., Hindin, M.J., Souza, J.P., et al. The prevalence of maternal near miss: a systematic review. BJOG 119:6 (2012 May), 653–661.
20. [20] Lawn, J.E., Blencowe, H., Waiswa, P., et al. Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet 387:10018 (2016 February 6), 587–603.
21. [21] Vogel, J.P., Souza, J.P., Mori, R., et al. Maternal complications and perinatal mortality: findings of the World Health Organization multicountry survey on maternal and newborn health. BJOG 121:Suppl. 1 (2014 March), 76–88.
22. [22] Lawn, J.E., Blencowe, H., Oza, S., et al. Every newborn: progress, priorities, and potential beyond survival. Lancet 384:9938 (2014 July 12), 189–205.
23. [23] Backes, C.H., Markham, K., Moorehead, P., et al. Maternal preeclampsia and neonatal outcomes. J Pregnancy, 2011, 2011, 214365.
24. [24] Pijnenborg, R., Anthony, J., Davey, D.A., et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 98:7 (1991 July), 648–655.
25. [25] Roberts, J.M., Escudero, C., The placenta in preeclampsia. Pregnancy Hypertens 2:2 (2012 April 1), 72–83.
26. [26] Mason, E., Chandra-Mouli, V., Baltag, V., et al. Preconception care: advancing from 'important to do and can be done' to 'is being done and is making a difference'. Reprod Health, 11(Suppl. 3), 2014 September 26, S8.
27. [27] Prost, A., Colbourn, T., Seward, N., et al. Women's groups practising participatory learning and action to improve maternal and newborn health in low-resource settings: a systematic review and meta-analysis. Lancet 381:9879 (2013 May 18), 1736–1746.
28. [28] Colbourn, T., Nambiar, B., Bondo, A., et al. Effects of quality improvement in health facilities and community mobilization through women's groups on maternal, neonatal and perinatal mortality in three districts of Malawi: MaiKhanda, a cluster randomized controlled effectiveness trial. Int Health 5:3 (2013 September), 180–195.
29. [29] Khowaja, A.R., Mitton, C., Bryan, S., et al. Economic evaluation of community level interventions for pre-eclampsia (CLIP) in South Asian and African countries: a study protocol. Implement Sci, 10, 2015, 76.
30. [30] Basso, O., Wilcox, A.J., Weinberg, C.R., et al. Height and risk of severe pre-eclampsia. A study within the Danish national birth cohort. Int J Epidemiol 33:4 (2004 August), 858–863.
31. [31] Sohlberg, S., Stephansson, O., Cnattingius, S., et al. Maternal body mass index, height, and risks of preeclampsia. Am J Hypertens 25:1 (2012 January), 120–125.
32. [32] Dean, S.V., Lassi, Z.S., Imam, A.M., et al. Preconception care: nutritional risks and interventions. Reprod Health, 11(Suppl. 3), 2014 September 26, S3.
33. [33] Ahmed, T., Mahfuz, M., Ireen, S., et al. Nutrition of children and women in Bangladesh: trends and directions for the future. J Health Popul Nutr 30:1 (2012 March), 1–11.
34. [34] Laraia, B.A., Siega-Riz, A.M., Gundersen, C., Household food insecurity is associated with self-reported pregravid weight status, gestational weight gain, and pregnancy complications. J Am Diet Assoc 110:5 (2010 May), 692–701.
35. [35] Poston, L., Chappell, L.C., Is oxidative stress involved in the aetiology of pre-eclampsia?. Acta Paediatr Suppl 90:436 (2001 March), 3–5.
36. [36] Rumbold, A., Ota, E., Nagata, C., et al. Vitamin C supplementation in pregnancy. Cochrane Database Syst Rev, 9, 2015, CD004072.
37. [37] Rumbold, A., Ota, E., Hori, H., et al. Vitamin E supplementation in pregnancy. Cochrane Database Syst Rev, 9, 2015, CD004069.
38. [38] Hofmeyr, G.J., Lawrie, T.A., Atallah, A.N., et al. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev, 6, 2014, CD001059.
39. [39] Hofmeyr, G.J., Belizan, J.M., von Dadelszen, P., Low-dose calcium supplementation for preventing pre-eclampsia: a systematic review and commentary. BJOG 121:8 (2014 July), 951–957.
40. [40] Hofmeyr, G.J., Seuc, A.H., Betran, A.P., et al. The effect of calcium supplementation on blood pressure in non-pregnant women with previous pre-eclampsia: an exploratory, randomized placebo controlled study. Pregnancy Hypertens 5:4 (2015 October), 273–279.
41. [41] Agrawal, S., Fledderjohann, J., Vellakkal, S., et al. Adequately diversified dietary intake and iron and folic acid supplementation during pregnancy is associated with reduced occurrence of symptoms suggestive of pre-eclampsia or eclampsia in Indian women. PLoS One, 10(3), 2015, e0119120.
42. [42] Bhutta, Z.A., Das, J.K., Rizvi, A., et al. Evidence-based interventions for improvement of maternal and child nutrition: what can be done and at what cost?. Lancet 382:9890 (2013 August 3), 452–477.
43. [43] Leppalahti, S., Gissler, M., Mentula, M., et al. Is teenage pregnancy an obstetric risk in a welfare society? A population-based study in Finland, from 2006 to 2011. BMJ Open, 3(8), 2013, e003225.
44. [44] Kumar, A., Singh, T., Basu, S., et al. Outcome of teenage pregnancy. Indian J Pediatr 74:10 (2007 October), 927–931.
45. [45] Aliyu, M.H., Luke, S., Kristensen, S., et al. Joint effect of obesity and teenage pregnancy on the risk of preeclampsia: a population-based study. J Adolesc Health 46:1 (2010 January), 77–82.
46. [46] Saftlas, A.F., Rubenstein, L., Prater, K., et al. Cumulative exposure to paternal seminal fluid prior to conception and subsequent risk of preeclampsia. J Reprod Immunol 101–102 (2014 March), 104–110.
47. [47] Staff, A.C., Benton, S.J., von Dadelszen, P., et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension 61:5 (2013 May), 932–942.
48. [48] de Jonge, H.C., Azad, K., Seward, N., et al. Determinants and consequences of short birth interval in rural Bangladesh: a cross-sectional study. BMC Pregnancy Childbirth, 14, 2014, 427.
49. [49] United Nations Population Fund, RHCS update: the global programme to enhance reproductive health commodity security. 2010, UNFPA, New York.
50. [50] Neira, M., Kelley, E., Bahl, R., et al. Water, sanitation and hygiene in health care facilities: status in low and middle income countries and way forward. 2015, World Health Organization, Geneva.
51. [51] Campbell, O.M., Benova, L., Gon, G., et al. Getting the basic rights - the role of water, sanitation and hygiene in maternal and reproductive health: a conceptual framework. Trop Med Int Health 20:3 (2015 March), 252–267.
52. [52] Chweya, L., Democracy and organization of local governance in Kenya. Chitere, O.P., Mutiso, R., (eds.) Working with rural communities: participatory action research in Kenya, 2nd ed., 2014, University of Nairobi Press, Nairobi, 203–236.
53. [53] ten Hoope-Bender, P., de Bernis, L., Campbell, J., et al. Improvement of maternal and newborn health through midwifery. Lancet 384:9949 (2014 September 27), 1226–1235.
54. [54] Mother-baby friendly birthing facilities. Int J Gynaecol Obstet 128:2 (2015 February), 95–99.
55. [55] Miller, S., Lalonde, A., The global epidemic of abuse and disrespect during childbirth: history, evidence, interventions, and FIGO's mother-baby friendly birthing facilities initiative. Int J Gynaecol Obstet 131:Suppl. 1 (2015 October), S49–S52.
56. [56] Moyer, C.A., Adongo, P.B., Aborigo, R.A., et al. 'They treat you like you are not a human being': maltreatment during labour and delivery in rural northern Ghana. Midwifery 30:2 (2014 February), 262–268.
57. [57] Rasanen, J., Quinn, M.J., Laurie, A., et al. Maternal serum glycosylated fibronectin as a point-of-care biomarker for assessment of preeclampsia. Am J Obstet Gynecol 212:1 (2015 January), 82–89.
58. [58] Widmer, M., Cuesta, C., Khan, K.S., et al. Accuracy of angiogenic biomarkers at 20weeks' gestation in predicting the risk of pre-eclampsia: a WHO multicentre study. Pregnancy Hypertens 5:4 (2015 October), 330–338.
59. [59] Conde-Agudelo, A., Villar, J., Lindheimer, M., World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 104:6 (2004 December), 1367–1391.
60. [60] Lassi, Z.S., Mansoor, T., Salam, R.A., et al. Essential pre-pregnancy and pregnancy interventions for improved maternal, newborn and child health. Reprod Health, 11(Suppl. 1), 2014, S2.
61. [61] Dowswell, T., Carroli, G., Duley, L., et al. Alternative versus standard packages of antenatal care for low-risk pregnancy. Cochrane Database Syst Rev, 7, 2015, CD000934.
62. [62] Oakley, A., Origins and development of antenatal care. Effectiveness and satisfaction with antenatal care. 1982, Cambridge University Press, Cambridge, 1–21.
63. [63] von Dadelszen, P., Magee, L.A., Pre-eclampsia: an update. Curr Hypertens Rep, 16(8), 2014 August, 454.
64. [64] Magee, L.A., Abalos, E., von Dadelszen, P., et al. How to manage hypertension in pregnancy effectively. Br J Clin Pharmacol 72:3 (2011 September), 394–401.
65. [65] Which anticonvulsant for women with eclampsia? Evidence from the collaborative eclampsia Trial. Lancet 345:8963 (1995 June 10), 1455–1463.
66. [66] Altman, D., Carroli, G., Duley, L., et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 359:9321 (2002 June 1), 1877–1890.
67. [67] Fernando, D., Jayatilleka, A., Karunaratna, V., Pregnancy–reducing maternal deaths and disability in Sri Lanka: national strategies. Br Med Bull 67 (2003), 85–98.
68. [68] Gillon, T.E., Pels, A., von Dadelszen, P., et al. Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. PLoS One, 9(12), 2014, e113715.
69. [69] Nathan, H.L., de, G.A., Hezelgrave, N.L., et al. An accurate semiautomated oscillometric blood pressure device for use in pregnancy (including pre-eclampsia) in a low-income and middle-income country population: the Microlife 3AS1-2. Blood Press Monit 20:1 (2015 February), 52–55.
70. [70] Wen, S.W., Kramer, M.S., Hoey, J., et al. Terminal digit preference, random error, and bias in routine clinical measurement of blood pressure. J Clin Epidemiol 46:10 (1993 October), 1187–1193.
71. [71] Morris, R.K., Riley, R.D., Doug, M., et al. Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis. BMJ, 345, 2012, e4342.
72. [72] De Silva, D.A., Halstead, A.C., Cote, A.M., et al. Random urine albumin: creatinine ratio in high-risk pregnancy – is it clinically useful?. Pregnancy Hypertens 3:2 (2013 April), 112–114.
73. [73] Payne, B., Magee, L.A., Cote, A.M., et al. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can 33:6 (2011 June), 588–597.
74. [74] Kozic, J.R., Benton, S.J., Hutcheon, J.A., et al. Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can 33:10 (2011 October), 995–1004.
75. [75] Laskin, S., Payne, B., Hutcheon, J.A., et al. The role of platelet counts in the assessment of inpatient women with preeclampsia. J Obstet Gynaecol Can 33:9 (2011 September), 900–908.
76. [76] Livingston, J.R., Payne, B., Brown, M., et al. Uric Acid as a predictor of adverse maternal and perinatal outcomes in women hospitalized with preeclampsia. J Obstet Gynaecol Can 36:10 (2014 October), 870–877.
77. [77] Millman, A.L., Payne, B., Qu, Z., et al. Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can 33:7 (2011 July), 705–714.
78. [78] Yen, T.W., Payne, B., Qu, Z., et al. Using clinical symptoms to predict adverse maternal and perinatal outcomes in women with preeclampsia: data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study. J Obstet Gynaecol Can 33:8 (2011 August), 803–809.
79. [79] Payne, B.A., Hutcheon, J.A., Dunsmuir, D., et al. Assessing the incremental value of blood oxygen saturation (SpO(2)) in the miniPIERS (Pre-eclampsia integrated estimate of RiSk) risk prediction model. J Obstet Gynaecol Can 37:1 (2015 January), 16–24.
80. [80] Dunsmuir, D.T., Payne, B.A., Cloete, G., et al. Development of mHealth applications for pre-eclampsia triage. IEEE J Biomed Health Inform 18:6 (2014 November), 1857–1864.
81. [81] Lim, J., Cloete, G., Dunsmuir, D.T., et al. Usability and feasibility of PIERS on the Move: an mHealth app for pre-eclampsia triage. JMIR Mhealth Uhealth, 3(2), 2015, e37.
82. [82] Payne, B., Hodgson, S., Hutcheon, J.A., et al. Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG 120:1 (2013 January), 113–118.
83. [83] Akkermans, J., Payne, B., von Dadelszen, P., et al. Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. Eur J Obstet Gynecol Reprod Biol 179 (2014 August), 58–62.
84. [84] Agrawal, S., Maitra, N., Prediction of adverse maternal outcomes in preeclampsia using a risk prediction model. J Obstet Gynecol India, 2015, 1–8 [Epub ahead of print].
85. [85] Winje, B.A., Wojcieszek, A.M., Gonzalez-Angulo, L.Y., et al. Interventions to enhance maternal awareness of decreased fetal movement: a systematic review. BJOG, 2015 December 2.
86. [86] Payne, B.A., Groen, H., Ukah, U.V., et al. Development and internal validation of a multivariable model to predict perinatal death in pregnancy hypertension. Pregnancy Hypertens 5:4 (2015 October), 315–321.
87. [87] Grivell, R.M., Wong, L., Bhatia, V., Regimens of fetal surveillance for impaired fetal growth. Cochrane Database Syst Rev, 6, 2012, CD007113.
88. [88] Kaur, S., Picconi, J.L., Chadha, R., et al. Biophysical profile in the treatment of intrauterine growth-restricted fetuses who weigh <1000 g. Am J Obstet Gynecol, 199(3), 2008 September, 264.
89. [89] Payne, B.A., Kyle, P.M., Lim, K., et al. An assessment of predictive value of the biophysical profile in women with preeclampsia using data from the fullPIERS database. Pregnancy Hypertens 3:3 (2013 July), 166–171.
90. [90] Shalev, E., Zalel, Y., Weiner, E., A comparison of the nonstress test, oxytocin challenge test, Doppler velocimetry and biophysical profile in predicting umbilical vein pH in growth-retarded fetuses. Int J Gynaecol Obstet 43:1 (1993 October), 15–19.
91. [91] Magee, L.A., von Dadelszen, P., Rey, E., et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 372:5 (2015 January 29), 407–417.
92. [92] Magee, L.A., von Dadelszen, P., Singer, J., et al. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension in Pregnancy Study (CHIPS) Trial. BJOG, 2015 August 11.
93. [93] Lalani, S., Firoz, T., Magee, L.A., et al. Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. J Obstet Gynaecol Can 35:3 (2013 March), 215–223.
94. [94] Gordon, R., Magee, L.A., Payne, B., et al. Magnesium sulphate for the management of preeclampsia and eclampsia in low and middle income countries: a systematic review of tested dosing regimens. J Obstet Gynaecol Can 36:2 (2014 February), 154–163.
95. [95] Bickford, C.D., Magee, L.A., Mitton, C., et al. Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis. BMC Health Serv Res, 13, 2013, 527.
96. [96] Magee, L., Sawchuck, D., Synnes, A., et al. SOGC Clinical Practice Guideline. Magnesium sulphate for fetal neuroprotection. J Obstet Gynaecol Can 33:5 (2011 May), 516–529.
97. [97] Althabe, F., Belizan, J.M., McClure, E.M., et al. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial. Lancet 385:9968 (2015 February 14), 629–639.
98. [98] Crowther, C.A., McKinlay, C.J., Middleton, P., et al. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database Syst Rev, 7, 2015, CD003935.
99. [99] Hutcheon, J.A., Lisonkova, S., Magee, L.A., et al. Optimal timing of delivery in pregnancies with pre-existing hypertension. BJOG 118:1 (2011 January), 49–54.
100. [100] Ganzevoort, W., Sibai, B.M., Temporising versus interventionist management (preterm and at term). Best Pract Res Clin Obstet Gynaecol 25:4 (2011 August), 463–476.
101. [101] Irgens, H.U., Reisaeter, L., Irgens, L.M., et al. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 323:7323 (2001 November 24), 1213–1217.
102. [102] McCowan, L.M., Pryor, J., Harding, J.E., Perinatal predictors of neurodevelopmental outcome in small-for-gestational-age children at 18 months of age. Am J Obstet Gynecol 186:5 (2002 May), 1069–1075.